+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vivus - logo

VIVUS is a biopharmaceutical company that develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company’s lead product Qsymia is a combination appetite suppressant/stimulant and seizure medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in overweight and obese adults. VIVUS was founded in 1991 and is headquartered in Campbell, California.

From
Exocrine Pancreatic Insufficiency Market Report 2025 - Product Thumbnail Image

Exocrine Pancreatic Insufficiency Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
GABAA Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABAA Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Benzodiazepine Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Benzodiazepine Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Obesity: Competitive Landscape to 2026 - Product Thumbnail Image

Obesity: Competitive Landscape to 2026

  • Report
  • October 2018
  • 50 Pages
  • Global
From
Kainate Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Kainate Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
AMPA Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

AMPA Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
VIVUS LLC. - Company Profile and SWOT Analysis - Product Thumbnail Image

VIVUS LLC. - Company Profile and SWOT Analysis

  • SWOT Analysis
  • January 2025
  • 30 Pages
From
Vivus, Inc - Strategy, SWOT and Corporate Finance Report - Product Thumbnail Image

Vivus, Inc - Strategy, SWOT and Corporate Finance Report

  • SWOT Analysis
  • March 2022
  • 39 Pages
From
Loading Indicator